Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Top Cited Papers
- 1 December 2004
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 364 (9450), 2021-2029
- https://doi.org/10.1016/s0140-6736(04)17514-4
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Lessons from the withdrawal of rofecoxib: ***BMJ, 2004
- Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General PopulationCirculation, 2004
- Commentary: Hormone replacement therapy and coronary heart disease: four lessonsInternational Journal of Epidemiology, 2004
- Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled TrialJournal of the American Geriatrics Society, 2004
- Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trialsCurrent Medical Research and Opinion, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarctionPublished by Wiley ,2002
- Rofecoxib, a New Cyclooxygenase 2 Inhibitor, Shows Sustained Efficacy, Comparable With Other Nonsteroidal Anti-inflammatory Drugs: A 6-Week and a 1-Year Trial in Patients With OsteoarthritisArchives of Family Medicine, 2000
- The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritisClinical Therapeutics, 1999
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritisGastroenterology, 1999